DSHEA: The Law That Makes Honey Packs Legal

The Dietary Supplement Health and Education Act of 1994 (DSHEA) is the foundational federal law for the US supplement industry. It defined "dietary supplement" as a product taken by mouth containing a "dietary ingredient" — vitamins, minerals, herbs, amino acids, or other dietary substances — and crucially, it treated supplements as a category of food rather than drugs. That classification is the reason honey packs can be sold without pre-market FDA approval.

Before DSHEA, the FDA had been moving toward stricter regulation of supplements, particularly herbs marketed for health benefits. DSHEA reversed that trajectory. It codified that supplements do not require pre-market safety or efficacy testing, do not require FDA review of labeling claims (within limits), and are the manufacturer's responsibility to keep safe. The FDA's role was redefined as post-market enforcement — it can act only after a problem is identified.

DSHEA allows supplement labels to make "structure/function claims" — statements like "supports cardiovascular health" or "promotes male vitality" — without FDA review, as long as the label includes the disclaimer "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease." That disclaimer is why nearly every honey pack label reads the way it does.

The loophole is that structure/function language is vague enough to imply substantial benefits without making an explicit drug claim. A product that says "promotes male performance" is legally a supplement. The same product saying "treats erectile dysfunction" would be an unapproved drug. In practice, honey pack marketing operates in the gray zone between those two framings.

FDA's consumer supplement guidance explains that, under DSHEA, FDA generally does not approve dietary supplements for safety and effectiveness before they are marketed. That post-market structure is the reason honey-pack enforcement often appears as a timeline rather than a pre-sale approval checkpoint.

That sequence means a product can be physically available before it is publicly named. Use the Safety Alerts hub and FDA honey-products page together, and do not treat FDA silence as approval.

DSHEA does not require:

• Pre-market safety testing of new products (except for a narrower "new dietary ingredient" category).
• Pre-market efficacy testing or proof that marketing claims are true.
• Third-party verification of ingredient identity or purity.
• FDA approval of labels or packaging before sale.
• Mandatory reporting of adverse events from every product (though a 2006 amendment added serious-adverse-event reporting for manufacturers).

What it does require is that manufacturers follow Current Good Manufacturing Practices (cGMP) for supplements, accurately label ingredients, and not make explicit drug claims. Enforcement of those rules is reactive — the FDA responds to complaints, adverse events, and targeted inspections rather than reviewing each new product before it reaches shelves.

DSHEA was written with vitamins, minerals, and traditional botanicals in mind. It did not anticipate a market segment in which products routinely contain undeclared prescription drugs. The law's enforcement mechanics — reactive, complaint-driven, resource-limited — are particularly ill-suited to products whose adulteration is invisible without laboratory analysis.

The result is a predictable pattern: product enters the market, circulates for months or years, eventually gets tested after an adverse event, gets flagged, the brand rebrands or disappears, and a near-identical product returns under a new name. DSHEA provides no structural pressure against that cycle. Fixing it would require legislative change.

Recurring reform proposals include mandatory product listing with the FDA (so the agency at least knows what is on the market), mandatory recall authority, required pre-market notification for new finished products, and expanded cGMP inspection funding. Some proposals would also tighten structure/function-claim standards to reduce the gap between "supports" language and implicit disease claims.

None of these reforms have passed. Industry lobbying has successfully framed stricter regulation as a burden on legitimate supplement companies, and there is no federal-level constituency pushing hard on honey-pack-specific harms. Until the statute changes, DSHEA continues to define the legal space. Understanding that space is the precondition for consumer self-protection — start with the legal overview.